A Pilot Surveillance Study to Monitor Natural Killer Cells and Circulating Tumor Cells in Women With Previously Treated Non-metastatic Triple Negative Breast Cancer and Women With Previously Treated Non-metastatic Breast Cancer With a Confirmed BRCA Mutation.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cynvenio Biosystems
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Signed Informed Consent Form.
Female.
Over 18 years of age.
Previously Treated Non-metastatic Triple Negative Breast Cancer or Women with Previously Treated Non-metastatic Breast Cancer With a confirmed BRCA Mutation who have completed therapy within three years of enrollment in this study.
Subject may be invited to annual review of the Subject Information and Donation Schedule by email or mail follow up for five years after sampling.
Subject provides written authorization for use and disclosure of protected health information (PHI).
You may not be if
Any conditions inappropriate for blood drawing.
Known active viral or bacterial infection at time of blood draw.
Known HIV, Hepatitis B, or Hepatitis C infection.
Clareo Health | A Pilot Surveillance Study to Monitor Natural Killer Cells and Circulating Tumor Cells in Women With Previously Treated Non-metastatic Triple Negative Breast Cancer and Women With Previously Treated Non-metastatic Breast Cancer With a Confirmed BRCA Mutation.
